Moreover, recent studies also suggested that NLRP3 gene polymorphism could predict the interferon beta (IFN-β) efficacy in MS patients’ treatment (Malhotra et al., 2015; Imani et al., 2018; Inoue et al., 2012b). This evidence concerns the gene NLRP3 and myeloid sarcoma.